May 5 (Reuters) – U.S. Food and Drug Administration Commissioner Dr. Marty Makary on Tuesday defended the agency’s decision to not approve Replimune’s drug for advanced skin cancer.
“If you read our what we call our complete response letter, you will see the details of the FDA logic,” Makary said in an interview on CNBC.
Replimune shares were down 5% in morning trading.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)